| gap-pubmed-20260410- | What are the specific molecular cascades by which electrical stimulation enhance | open | 0.80 | 0.00 | 2026-04-10 | 0 | | nerve-regeneration |
| gap-pubmed-20260410- | How does hnRNPL-MTNR1A dysregulation in nephropathy relate to neurological compl | open | 0.57 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanism explains why MTNR1A shows diurnal rhythm while hnRNPL does not in | open | 0.64 | 0.00 | 2026-04-10 | 0 | | circadian-neurobiology |
| gap-pubmed-20260410- | What determines the optimal 10% BYHWD serum concentration for neuroprotection? | open | 0.75 | 0.00 | 2026-04-10 | 0 | | stroke-recovery |
| gap-pubmed-20260410- | How does BYHWD selectively modulate cAMP/PKA/CREB pathway components given its m | open | 0.80 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How do membrane-bound TREM2 and soluble sTREM2 functionally interact in AD patho | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether TREM2 shedding occurs via proteolytic cleavage versus al | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do findings from preclinical mTOR-related ASD models translate to clinical p | open | 0.75 | 0.00 | 2026-04-10 | 0 | | translational-neuroscience |
| gap-pubmed-20260410- | What specific mechanisms link mTOR hyperactivation to disrupted autophagy, neura | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | Why does PPARγ require HSP90β specifically for stability rather than other HSP90 | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the Axl/ERK pathway specifically regulate HSP90β transcription or stabi | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the mechanism by which Aβ stress specifically decreases HSP90β expressio | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the specificity and efficiency of mitochondrial uptake by differ | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurotherapeutics |
| gap-pubmed-20260410- | How do transplanted mitochondria simultaneously provide neuroprotection and redu | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the molecular mechanisms by which transplanted mitochondria integrate a | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does HIF-1α activation occur in other ALS genetic variants or is this specific t | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which specific factors in conditioned medium from healthy astrocytes rescue moto | partially_addressed | 0.87 | 0.00 | 2026-04-10 | 1 | 2026-04-25 | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanism causes VCP mutations to trigger aberrant HIF-1α activat | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do lipid genetic variants influence brain gene expression independently of A | resolved | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link lipid genetic risk variants to HMCN2 expression i | resolved | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does α-phenyl tropolone provide neuroprotection if HDAC2/8 levels weren't me | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does HDAC6 co-localize with apoptotic cells while other HDACs do not in stro | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive HDAC6-specific upregulation and nuclear transloc | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What adaptive personalization algorithms optimize digital intervention delivery | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do mobile app-based BPSD interventions show efficacy only in patients with h | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does TREM2 regulate the development and maintenance of the rod-shaped microg | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do rod-shaped microglia mechanistically remodel excitatory synaptic inputs t | open | 0.76 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What molecular mechanisms enable rod-shaped microglia to specifically recognize | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Does LRRK2's role as a lysosomal volume sensor explain the pathogenic mechanism | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does LRRK2 activation on non-swollen lysosomes occur when only distant lysos | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the molecular mechanism by which lysosomal volume changes are sensed and | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does proteolethargy contribute to neurodegeneration in chronic diseases like | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the molecular mechanism linking cysteine oxidation to reduced protein mo | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do SCFA and BHB mechanistically coordinate neuroprotection across different | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What biomarkers can guide personalized IF interventions in cognitively vulnerabl | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How should IF protocols be optimized for individual variability in neurodegenera | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the temporal relationship between Aβ reduction and neuronal apoptosis in | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does SHD selectively target PDE4B versus other PDE4 isoforms in neuronal apo | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the direct molecular targets of curcumin that lead to p53 pathway inhib | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why is the medial prefrontal cortex selectively vulnerable to CORT-induced p53-m | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does p53 activation specifically upregulate DDIT4 to trigger NF-κB-mediated | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do VTA dopamine and GABA neurons express different HCN channel subunit profi | resolved | 0.79 | 0.00 | 2026-04-10 | 0 | | cellular-neuroscience |
| gap-pubmed-20260410- | What molecular mechanisms drive cAMP-mediated upregulation of HCN channels follo | open | 0.82 | 0.00 | 2026-04-10 | 0 | | addiction-neurobiology |
| gap-pubmed-20260410- | How does caspase-3-mediated apoptosis mechanistically enhance herpesvirus replic | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do herpesviruses evolve to induce apoptosis when it typically serves as host | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Which specific molecular interactions between parkin and synaptic proteins repre | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does early synaptic damage caused by PARK2 mutations lead to progressive dop | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which parkin regulates excitatory | open | 0.85 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What is the temporal relationship between JTW's anti-inflammatory effects and Nr | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does the 10:1 ratio of coptis chinensis to cinnamon in JTW specifically opti | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |